By Matthew Carr At the end of October, I wrote that the next wave for cannabis companies would be “buyer’s remorse.”
That’s because pot stocks have fallen flat on their faces over the past six months.
The mergers and acquisitions that fueled companies’ champagne wishes and caviar dreams were inked when share prices were sky high.
But now these companies are battered and bruised.
We’d already heard that MedMen Enterprises (OTC: MMNFF) abandoned its $682 million takeover of PharmaCann.
I said then that unless some major headway was made on marijuana mergers and acquisitions, the MedMen fallout would merely be the first. And that at least half of …read more
